Tuesday, Oct 13, 1987
South San Francisco, Calif. -- October 13, 1987 --Genentech, Inc. announced today that its foreign licensee, Boehringer Ingelheim International GmbH, has received approval to market tissue plasminogen activator (t-PA)in the Federal Republic of Germany (West Germany). T-PA, which will be marketed outside North America under the trademark Actilyse®, has been approved for dissolving blood clots that cause heart attacks. It is marketed in West Germany by the firm Dr. Karl Thomae GmbH, an affiliate of the Boehringer Ingelheim group, which has already begun shipping Actilyse®.
"As the largest market for coronary thrombolysis and the third largest pharmaceutical market in the free world, approval in West Germany is particularly significant," stated Robert A. Swanson, Genentech's Chief Executive Officer.
Actilyse has been approved in seven countries to date, including Austria, France, Brazil, New Zealand, the Philippines and South Korea. Genentech will receive royalties on product sales in these countries.
Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #